GM&C Life Sciences Fund

"Current treatments for these conditions require frequent hospitalisations for intravenous treatment with high doses of diuretics which is not only inconvenient for patients and associated with a risk of kidney injury but also costly. We offer a gentler, safer solution that can be delivered at home, offering patients better quality of life and reducing hospital admissions and costs to healthcare providers. This round of funding enables Renephra to carry out pilot clinical studies to demonstrate a viable success rate in target patients and to understand factors related to success. This is an essential next step for the company in advancing this much needed and promising technology through to regulatory approvals and making it available to clinicians and patients."